Inhaled vaccine developer Ansun BioPharma, formerly NexBio, has announced that the US Attorney's office investigation of misconduct by the company's former CEO and CFO has been dismissed. As part of that investigation, the US Federal Bureau of Investigation (FBI) raided the California headquarters of NexBio in August 2011. According to a January 2015 announcement … [Read more...] about Investigation into Ansun BioPharma dismissed
News
Invion and Hovione partner on inhaled zafirlukast for asthma
Hovione and Invion will partner on the development of Invion's INV104 zafirlukast DPI for the treatment of asthma, the companies have announced. Hovione will provide the device as well as particle engineering, formulation, and manufacturing services; Invion will take responsibility for pre-clinical and clinical development as well as regulatory submissions. Hovione … [Read more...] about Invion and Hovione partner on inhaled zafirlukast for asthma
Pulmatrix gets two new patents for its iSPERSE inhalation powder technology
The US Patent and Trademark Office has issued Pulmatrix two new patents, US Patent No. 8,992,983, "Respirably dry powder comprising calcium lactate, sodium chloride and leucine" and US Patent No. 9,061,352, "Dry powder formulations and methods for treating pulmonary diseases," the company said. Pulmatrix now has 36 patents covering technology related to the iSPERSE … [Read more...] about Pulmatrix gets two new patents for its iSPERSE inhalation powder technology
Adherium (formerly Nexus6) partners with AstraZeneca
Smartinhaler maker Adherium (formerly Nexus6) has announced a new deal to provide AstraZeneca with devices and sensors for use in asthma and COPD patient support programs. AstraZeneca has already used the Adherium technology in clinical trials. Studies have verified that Smartinhaler use significantly increases adherence to asthma medications both in children and … [Read more...] about Adherium (formerly Nexus6) partners with AstraZeneca
Acorda gets Gates Foundation grant for dry powder lung surfactant development
Acorda Therapeutics has announced that it received a $1.4 million grant from the Bill & Melinda Gates Foundation for development of a dry powder lung surfactant for the treatment of neonatal respiratory distress syndrome (RDS) based on its ARCUS inhalation platform, as well as a delivery system. The company will develop the formulation in conjunction with the … [Read more...] about Acorda gets Gates Foundation grant for dry powder lung surfactant development
Propeller Health’s inhaler monitoring platform approved for use with Diskus and Respimat
Propeller Health has received 510(k) clearance from the FDA to market the Propeller inhaler monitoring platform for use with the Diskus DPI and with the Respimat SMI, the company announced. Two versions of the Propeller platform have previously been approved for use with MDIs, most recently in 2014. The platform includes Bluetooth-enabled sensors that snap onto … [Read more...] about Propeller Health’s inhaler monitoring platform approved for use with Diskus and Respimat
Amneal’s generic version of Tobi inhalation solution approved by FDA
The FDA has approved Amneal Pharmaceuticals's generic version of Tobi tobramycin inhalation solution, the company said. The product is the New Jersey-based generic pharmaceutical company's first inhalation solution. Amneal co-CEO and Chairman Chirag Patel said, "Tobramycin is extremely exciting for us in that it’s a new dosage form for Amneal—proof we’re … [Read more...] about Amneal’s generic version of Tobi inhalation solution approved by FDA
Inhalation Sciences adds new investors
Swedish-based Inhalation Sciences AB (ISAB) has added new minority shareholders Stockholms Affärsänglar (STOAF) and Almi Invest, "with a significant initial capital investment," the company said. According to ISAB, that investment is the first phase out of three. ISAB's PreciseInhale system is used to aerosolize very small amounts of inhalable dry powders for … [Read more...] about Inhalation Sciences adds new investors
OptiNose reports positive results from Phase 1 trial of intranasal oxytocin for autism
OptiNose has announced that a study comparing OPN-300 intranasal oxytocin to intravenous oxytocin for the treatment of autism showed the achievement of similar blood levels but significantly greater social-cognitive effects after intranasal administration. The results were published online July 14, 2015 in Translational Psychiatry. The randomized, … [Read more...] about OptiNose reports positive results from Phase 1 trial of intranasal oxytocin for autism
Inhaled Ebola vaccine shows promise
A study published July 13, 2015 in the Journal of Clinical investigation demonstrated that an inhaled vaccine created by a team from The University of Texas Medical Branch at Galveston (UTMB) and the National Institutes of Health protected primates against the Ebola virus. The vaccine was aerosolized using a nebulizer and delivered through a mask to a group of … [Read more...] about Inhaled Ebola vaccine shows promise